Eloxx Pharmaceuticals (ELOX) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsTrends ELOX vs. KPRX, TLPH, CELZ, PHIO, ABVC, BCLI, SLXN, ADXN, NEUP, and TRAWShould you be buying Eloxx Pharmaceuticals stock or one of its competitors? The main competitors of Eloxx Pharmaceuticals include Kiora Pharmaceuticals (KPRX), Talphera (TLPH), Creative Medical Technology (CELZ), Phio Pharmaceuticals (PHIO), ABVC BioPharma (ABVC), Brainstorm Cell Therapeutics (BCLI), Silexion Therapeutics (SLXN), Addex Therapeutics (ADXN), Neuphoria Therapeutics Inc. - Common Stock (NEUP), and Traws Pharma (TRAW). These companies are all part of the "pharmaceutical products" industry. Eloxx Pharmaceuticals vs. Kiora Pharmaceuticals Talphera Creative Medical Technology Phio Pharmaceuticals ABVC BioPharma Brainstorm Cell Therapeutics Silexion Therapeutics Addex Therapeutics Neuphoria Therapeutics Inc. - Common Stock Traws Pharma Eloxx Pharmaceuticals (NASDAQ:ELOX) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, community ranking, risk, valuation and dividends. Is ELOX or KPRX more profitable? Kiora Pharmaceuticals' return on equity of 21.32% beat Eloxx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eloxx PharmaceuticalsN/A N/A N/A Kiora Pharmaceuticals N/A 21.32%16.39% Which has more volatility & risk, ELOX or KPRX? Eloxx Pharmaceuticals has a beta of -1326.75, suggesting that its stock price is 132,775% less volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals has a beta of -0.46, suggesting that its stock price is 146% less volatile than the S&P 500. Do analysts rate ELOX or KPRX? Kiora Pharmaceuticals has a consensus target price of $10.00, suggesting a potential upside of 216.86%. Given Kiora Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Kiora Pharmaceuticals is more favorable than Eloxx Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eloxx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Kiora Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Does the MarketBeat Community believe in ELOX or KPRX? Kiora Pharmaceuticals received 4 more outperform votes than Eloxx Pharmaceuticals when rated by MarketBeat users. Likewise, 73.91% of users gave Kiora Pharmaceuticals an outperform vote while only 43.33% of users gave Eloxx Pharmaceuticals an outperform vote. CompanyUnderperformOutperformEloxx PharmaceuticalsOutperform Votes1343.33% Underperform Votes1756.67% Kiora PharmaceuticalsOutperform Votes1773.91% Underperform Votes626.09% Do institutionals and insiders believe in ELOX or KPRX? 2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 20.2% of Eloxx Pharmaceuticals shares are held by company insiders. Comparatively, 1.5% of Kiora Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has stronger earnings & valuation, ELOX or KPRX? Kiora Pharmaceuticals has higher revenue and earnings than Eloxx Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEloxx PharmaceuticalsN/AN/A-$36.06MN/AN/AKiora Pharmaceuticals$16M0.59-$12.51MN/AN/A Does the media refer more to ELOX or KPRX? In the previous week, Kiora Pharmaceuticals had 2 more articles in the media than Eloxx Pharmaceuticals. MarketBeat recorded 2 mentions for Kiora Pharmaceuticals and 0 mentions for Eloxx Pharmaceuticals. Kiora Pharmaceuticals' average media sentiment score of 1.89 beat Eloxx Pharmaceuticals' score of 0.00 indicating that Kiora Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Eloxx Pharmaceuticals Neutral Kiora Pharmaceuticals Very Positive SummaryKiora Pharmaceuticals beats Eloxx Pharmaceuticals on 14 of the 15 factors compared between the two stocks. Remove Ads Get Eloxx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELOX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELOX vs. The Competition Export to ExcelMetricEloxx PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$3.06B$5.62B$8.05BDividend YieldN/A1.47%4.89%4.04%P/E RatioN/A27.8023.7718.95Price / SalesN/A367.40380.82116.93Price / CashN/A168.6838.0534.62Price / BookN/A3.436.854.22Net Income-$36.06M-$71.72M$3.19B$246.59M Eloxx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELOXEloxx PharmaceuticalsN/AN/AN/AN/A$0.00N/A0.0030Gap DownKPRXKiora Pharmaceuticals2.1068 of 5 stars$3.07-5.5%$10.00+225.7%-45.9%$9.21M$16M0.0010Short Interest ↓News CoverageTLPHTalphera3.0296 of 5 stars$0.54-3.5%$4.33+702.5%-50.0%$9.20M$281,000.00-0.7819Positive NewsCELZCreative Medical Technology0.8405 of 5 stars$5.22+5.0%N/A-40.8%$9.13M$11,000.00-1.375Short Interest ↑Gap UpPHIOPhio Pharmaceuticals3.165 of 5 stars$1.32-7.0%$4.00+203.0%-85.8%$9.09MN/A-0.1210Short Interest ↑ABVCABVC BioPharma0.5908 of 5 stars$0.69+0.0%N/A-46.3%$8.96M$509,788.00-0.8030Short Interest ↑Positive NewsBCLIBrainstorm Cell Therapeutics3.9663 of 5 stars$1.56-2.5%$30.00+1,823.1%-66.8%$8.90MN/A-0.3340Analyst ForecastNews CoverageGap UpSLXNSilexion TherapeuticsN/A$1.05-1.9%$9.00+757.1%N/A$8.84MN/A0.00N/AGap DownADXNAddex Therapeutics2.0651 of 5 stars$8.24-3.1%$30.00+264.1%-38.7%$8.73M$556,045.00-24.2330Short Interest ↓Positive NewsNEUPNeuphoria Therapeutics Inc. - Common Stock2.1082 of 5 stars$4.93-5.2%$21.00+326.0%N/A$8.66M$662,715.000.00N/AUpcoming EarningsPositive NewsTRAWTraws Pharma0.9128 of 5 stars$2.29-30.8%N/AN/A$8.36M$226,000.00-0.0217High Trading Volume Remove Ads Related Companies and Tools Related Companies Kiora Pharmaceuticals Competitors Talphera Competitors Creative Medical Technology Competitors Phio Pharmaceuticals Competitors ABVC BioPharma Competitors Brainstorm Cell Therapeutics Competitors Silexion Therapeutics Competitors Addex Therapeutics Competitors Neuphoria Therapeutics Inc. - Common Stock Competitors Traws Pharma Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ELOX) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredFormer CIA to Trump – Will you Shut down this secret lab?Deep in the sands of New Mexico lies a government lab so secret it makes Area 51 look like a tourist spot… ...Paradigm Press | SponsoredDeFi Coin on Verge of Breakout!We’re Opening the Ultimate Crypto Vault… Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eloxx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eloxx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
